A Review on Efficacy and Safety of SGLT2 Inhibitors as Add-on Therapy with Metformin.
10.24304/kjcp.2018.28.3.243
- Author:
Kyeong Hye JEONG
1
Author Information
1. College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea. jnkh7@cau.ac.kr
- Publication Type:Original Article
- Keywords:
SGLT2 inhibitors;
metformin;
dapagliflozin;
empagliflozin;
ipragliflozin
- MeSH:
Blood Pressure;
Glucose;
Humans;
Hypotension;
Insurance;
Korea;
Metformin*;
Pharmacokinetics;
Weight Loss
- From:Korean Journal of Clinical Pharmacy
2018;28(3):243-249
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The new type of diabetes treatment, SGLT2 inhibitors, has been approved for monotherapy and combination therapy, but medical insurance is only allowed in combination therapy with metformin, which is the first choice for type 2 diabetes treatment. METHODS: The SGLT2 inhibitors prescribed in Korea are dapagliflozin, empagliflozin and ipragliflozin. A review was conducted using Pubmed to evaluate efficacy and safety for these medications with metformin combination therapy. 10 studies were selected by searching for keywords and related references and were reviewed in full. The mechanism of action, pharmacokinetics, and the economics of treatment with SGLT2 inhibitors were examined. RESULTS: SGLT2 inhibitors had moderate glycemic control when added to the treatment of patients with type 2 diabetes who were not being regulated by metformin monotherapy. They also showed positive effects such as weight loss, as well as the lowering of blood pressure. Hypotension and serious side effects were relatively low. However, the risk of genital infection was increased. CONCLUSION: The SGLT2 inhibitors are a new class of drugs that promote glucose excretion in the urine. They are a good choice for combination therapy with metformin for the treatment of type 2 diabetes, with weight loss and very low risk of serious side effects.
